No one should face hereditary cancer alone.

Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.

Hereditary Cancer Info > Risk Management > Ovarian Cancer Chemoprevention

Toggle Menu

Ovarian Cancer Chemoprevention

Learn about the steps that people at high risk for cancer can take to manage their risk and protect their health.

Advanced Reading

Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers
Kotsopoulos, J Lubinski, J, Moller, et al., "Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers," Breast Cancer Research and Treatment, Vol. 143, No. 3, pp. 579-586, February 2014.

Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis
Friebel, T.M., Domchek, S.M., Rebbeck, T.R., “Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: Systematic Review and Meta-Analysis,” Journal of the National Cancer Institute, (2014), Volume 106, Number 6. (Free full text available)

Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis
Moorman, P.G., Myers, E.R., et al. “Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis.” Journal of Clinical Oncology (2013), Volume 31, Number 33: p. 4188-98. (Free full text available)

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
A S Whittemore, R R Balise, P D P Pharoah, R A DiCioccio, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), I Oakley-Girvan, S J Ramus, M Daly, M B Usinowicz, K Garlinghouse-Jones, B A J Ponder, S Buys, R Senie, I Andrulis, E John, J L Hopper and M S Piver. British Journal of Cancer. Volume 91, Number 11, p. 1911-1915, November 2004.

Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Steven A. Narod, Marie-Pierre Dubé, Jan Klijn, Jan Lubinski, Henry T. Lynch, Parviz Ghadirian, Diane Provencher, Ketil Heimdal, Pal Moller, Mark Robson, Kenneth Offit, Claudine Isaacs, Barbara Weber, Eitan Friedman, Ruth Gershoni-Baruch, Gad Rennert, Barbara Pasini, Theresa Wagner, Mary Daly, Judy E. Garber, Susan L. Neuhausen, Peter Ainsworth, Hakan Olsson, Gareth Evans, Michael Osborne, Fergus Couch, William D. Foulkes, Ellen Warner, Charmaine Kim-Sing, Olufunmilayo Olopade, Nadine Tung, Howard M. Saal, Jeffrey Weitzel, Sofia Merajver, Marion Gauthier-Villars, Helena Jernstrom, Ping Sun, Jean-Sebastien Brunet. Journal of the National Cancer Institute. Volume 94, Number 23: p. 1773-1779, December 2002.

Effect of Fenretinide on Ovarian Carcinoma Occurrence
Giuseppe De Palo, Luigi Mariani, Tiziana Camerini, Ettore Marubini, Franca Formelli, Barbara Pasini, Andrea Decensi and Umberto Veronesi. Gynecologic Oncology. Volume 86, Issue 1: p 24-27, July 2002.

Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a BRCA1 or BRCA2 Mutation
Baruch Modan, Hartge, P., Hirsh-Yechezkel, G., Chetrit, A., Lubin, F., Beller, U., Ben-Baruch, G., Fishman,A., Menczer, J., Struewing, J., Tucker, M., Ebbers, S., Friedman, E., Piura, B., Wacholder, S., for the National Israel Ovarian Cancer Study Group. New England Journal of Medicine. Volume 345, Number 4: p. 235-240, July 2001.

Oral Contraceptives and the Risk of Hereditary Ovarian Cancer
Steven A. Narod, M.D., Harvey Risch, M.D., Ph.D., Roxana Moslehi, M.Sc., Anne Dørum, M.D., Susan Neuhausen, Ph.D., Hakan Olsson, M.D., Diane Provencher, M.D., Paolo Radice, Ph.D., Gareth Evans, M.D., Susan Bishop, M.Sc., Jean-Sébastien Brunet, M.Sc., Bruce A.J. Ponder, M.D., Ph.D., Jan G.M. Klijn, M.D., for The Hereditary Ovarian Cancer Clinical Study Group. New England Journal of Medicine. Volume 339: p. 424-428, August 1998.

FORCE:Facing Our Risk of Cancer Empowered